MedTrace Logo

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

NCT03077451 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-12-17

Study results available
· View outcomes & findings →

Summary

This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Recurrent Kaposi Sarcoma
  • Skin Kaposi Sarcoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nelfinavir Mesylate

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • The Emmes Company, LLC

    collaborator INDUSTRY

  • University of Arkansas

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • AIDS and Cancer Specimen Resource

    collaborator OTHER

  • Montefiore Medical Center

    collaborator OTHER

  • AIDS Malignancy Consortium

    lead NETWORK

Principal Investigators

  • Soren Gantt · AIDS Malignancy Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-13
Primary Completion
2022-05-23
Completion
2023-04-13
FDA Drug
Yes

Countries

  • United States
  • South Africa
  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03077451 on ClinicalTrials.gov